FDA approves Gilead's Yescarta cancer immunotherapy

(Reuters) - A new cancer therapy for a type of lymphoma developed by Kite Pharma, which was recently acquired by Gilead Sciences Inc, won U.S. Food and Drug Administration approval on Wednesday, six weeks ahead of schedule.